Vicky McKeever / CNBC
Link to story
Context
- Director of BARDA, U.S. agency key to helming vaccine development, leaves role suddenly; Congress recently tripled BARDA budget (Nicholas Florko / STAT)
- Moderna aiming to start full-scale production of untested coronavirus vaccine as early as July; Targeting Phase 3 trial in fall 2020 (William Feuer / CNBC)
- Coalition for Epidemic Preparedness Innovations backs Phase I & II trials for Novavax COVID-19 vaccine; Pledge amounts to up to $384M (John Carroll / Endpoints)
- Moderna reports positive Phase 1 coronavirus vaccine data; Antibodies were detected in all participants after 2 vaccine injections. If successful, targeting early 2021 launch. (Berkeley Lovelace Jr. / CNBC)
- Pfizer coronavirus vaccine could be ready for emergency use by fall; Early testing results coming as early as May (Jared S. Hopkins / The Wall Street Journal)
- Experts say Moderna hasn’t released enough information to properly assess early COVID-19 vaccine trial results (Helen Branswell / STAT)
- Trump administration to name Moncef Slaoui, former GSK vaccine head, to be ‘therapeutics czar’; Will lead government efforts to speed COVID-19 vaccine development (Dan Diamond / Politico)
